Pre-made Gancotamab benchmark antibody ( scFv, anti-ERBB2/HER2 therapeutic antibody, Anti-CD340/neu/MLN 19/NEU/NGL/TKR1/VSCN2 Antibody) for drug discovery and mechanism of action (MOA) research

Pre-Made Gancotamab biosimilar, scFv, Anti-ERBB2/HER2 Antibody: Anti-CD340/neu/MLN 19/NEU/NGL/TKR1/VSCN2 therapeutic antibody is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for biological drug disovery items including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.

Gancotamab, an antibody directed nanotherapeutic that encapsulates doxorubicin in a HER2-targeted liposome, that was being developed by Merrimack.

Order information

* GeneMedi provides NON-PROFIT PRICE to support Academic research. Please click inquiry for product quotation. → Inquiry

Catalog No.	Package	Price(In USD)	Qty (Quantity)	Sum(In USD)
GMP-Bios-ab-230-1mg	1mg	3090
GMP-Bios-ab-230-10mg	10mg	Inquiry
GMP-Bios-ab-230-100mg	100mg	Inquiry
GMP-Bios-ab-230-xmg	≥100mg	Inquiry
			Shipping Cost:	760.00
			Total:

Description

Products Name (INN Index)	Pre-Made Gancotamab biosimilar, scFv, Anti-ERBB2/HER2 Antibody: Anti-CD340/neu/MLN 19/NEU/NGL/TKR1/VSCN2 therapeutic antibody
INN Name	Gancotamab
Target	HER2
Format	scFv
Derivation
Species Reactivity	Human
CH1 Isotype	na
VD LC	Lambda
Highest_Clin_Trial (Jan '20)	Phase-II
Est. Status	Discontinued
100% SI Structure	None
99% SI Structure	None
95-98% SI Structure	None
Year Proposed	2018
Year Recommended	2019
Companies	Merrimack Pharmaceuticals;HERMES BioSciences
Conditions Approved	na
Conditions Active	na
Conditions Discontinued	Breast cancer
Development Tech	na